Humanization of Monoclonal Antibodies

Molecular Biology of B Cells

Volumn , Issue , 2004, Pages 533-545

  Tsurushita, Naoya ^a   Vásquez, Maximiliano ^a  

^a PROTEIN DESIGN LABS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84941626516     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012053641-2/50034-4     Document Type: Chapter

References (100)

1. Allcorn L.C., Martin A.C. SACS-self-maintaining database of antibody crystal structure information. Bioinformatics 2002, 18:175-181.
2. Baca M., Presta L.G., O'Connor S.J., Wells J.A. Antibody humanization using monovalent phage display. J Biol Chem 1997, 272:10678-10684.
3. Baselga J. Phase I and II clinical trials of transtuzumab. Ann Oncol 2001, 12:S49-S55.
4. Beiboer S.H., Reurs A., Roovers R.C., Arends J.W., Whitelegg N.R., Rees A.R., Hoogenboom H.R. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent. J Mol Biol 2000, 296:833-849.
5. Breitz H.B., Tyler A., Bjorn M.J., Lesley T., Weiden P.L. Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy. Clin Nucl Med 1997, 22:615-620.
6. Bruggemann M., Winter G., Waldmann H., Neuberger M.S. The immunogenicity of chimeric antibodies. J Exp Med 1989, 170:2153-2157.
7. Bumgardner G.L., Hardie I., Johnson R.W., Lin A., Nashan B., Pescovitz M.D., Ramos E., Vincenti F. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001, 72:839-845.
8. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., Rowland A.M., Kotts C., Carver M.E., Shepard H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992, 89:4285-4289.
9. Chothia C., Lesk A.M. The relation between the divergence of sequence and structure in proteins. EMBO J 1986, 5:823-826.
10. Chothia C., Lesk A.M. Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 1987, 196:901-917.
11. Chothia C., Lesk A.M., Gherardi E., Tomlinson I.M., Walter G., Marks J.D., Llewelyn M.B., Winter G. Structural repertoire of the human VH segments. J Mol Biol 1992, 227:799-817.
12. Chothia C., Lesk A.M., Tramontano A., Levitt M., Smith-Gill S.J., Air G., Sheriff S., Padlan E.A., Davies D., Tulip W.R., et al. Conformations of immunoglobulin hypervariable regions. Nature 1989, 342:877-883.
13. Clark M. Antibody humanization: A case of the 'Emperor's new clothes'?. Immunol Today 2000, 21:397-402.
14. Co M.S., Deschamps M., Whitley R.J., Queen C. Humanized antibodies for antiviral therapy. Proc Natl Acad Sci USA 1991, 88:2869-2873.
15. Cook G.P., Tomlinson I.M. The human immunoglobulin VH repertoire. Immunol Today 1995, 16:237-242.
16. Couto J.R., Blank E.W., Peterson J.A., Ceriani R.L. Anti-BA46 monoclonal antibody Mc3: Humanization using a novel positional consensus and in vivo and in vitro characterization. Cancer Res 1995, 55:1717-1722.
17. Couto J.R., Christian R.B., Peterson J.A., Ceriani R.L. Designing human consensus antibodies with minimal positional templates. Cancer Res 1995, 55:5973S-5977S.
18. Couto J.R., Padlan E.A., Blank E.W., Peterson J.A., Ceriani R.L. Humanization of KC4G3, an anti-human carcinoma antibody. Hybridoma 1994, 13:215-219.
19. De Pascalis R., Iwahashi M., Tamura M., Padlan E.A., Gonzales N.R., Santos A.D., Giuliano M., Schuck P., Schlom J., Kashmiri S.V. Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. J Immunol 2002, 169:3076-3084.
20. Delagrave S., Catalan J., Sweet C., Drabik G., Henry A., Rees A., Monath T.P., Guirakhoo F. Effects of humanization by variable domain resurfacing on the antiviral activity of a single-chain antibody against respiratory syncytial virus. Protein Eng 1999, 12:357-362.
21. Fagnani R. The immunogenicity of foreign monoclonal antibodies in human disease applications: Problems and current approaches. Immunol Ser 1994, 61:3-22.
22. Figini M., Obici L., Mezzanzanica D., Griffiths A., Colnaghi M.I., Winter G., Canevari S. Panning phage antibody libraries on cells: Isolation of human Fab fragments against ovarian carcinoma using guided selection. Cancer Res 1998, 58:991-996.
23. Foote J., Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 1992, 224:487-499.
24. Ghetie V., Ward E.S. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 2000, 18:739-766.
25. Gilliland L.K., Walsh L.A., Frewin M.R., Wise M.P., Tone M., Hale G., Kioussis D., Waldmann H. Elimination of the immunogenicity of therapeutic antibodies. J Immunol 1999, 162:3663-3671.
26. Glaser S.M., Vásquez M., Payne P.W., Schneider W.P. Dissection of the combining site in a humanized anti-Tac antibody. J Immunol 1992, 149:2607-2614.
27. Harfeldt E., Lake P., Nottage B., Ostberg L.G. Monoclonal antibody to herpes simplex virus and cell line producing same 1997, United States Patent, US 5646041, USA.
28. Holmes M.A., Buss T.N., Foote J. Conformational correction mechanisms aiding antigen recognition by a humanized antibody. J Exp Med 1998, 187:479-485.
29. Holmes M.A., Buss T.N., Foote J. Structural effects of framework mutations on a humanized anti-lysozyme antibody. J Immunol 2001, 167:296-301.
30. Holmes M.A., Foote J. Structural consequences of humanizing an antibody. J Immunol 1997, 158:2192-2201.
31. Hooks M.A., Wade C.S., Millikan W.J. Muromonab CD-3: A review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 1991, 11:26-37.
32. Hsiao K.C., Bajorath J., Harris L.J. Humanization of 60.3, an anti-CD18 antibody; importance of the L2 loop. Protein Eng 1994, 7:815-822.
33. Isaacs J.D., Waldmann H. Helplessness as a strategy for avoiding antiglobulin responses to therapeutic monoclonal antibodies. Ther Immunol 1994, 1:303-312.
34. Iwahashi M., Milenic D.E., Padlan E.A., Bei R., Schlom J., Kashmiri S.V. CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity. Mol Immunol 1999, 36:1079-1091.
35. Jaffers G.J., Fuller T.C., Cosimi A.B., Russell P.S., Winn H.J., Colvin R.B. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 1986, 41:572-578.
36. Jespers L.S., Roberts A., Mahler S.M., Winter G., Hoogenboom H.R. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (NY) 1994, 12:899-903.
37. Jones P.T., Dear P.H., Foote J., Neuberger M.S., Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321:522-525.
38. Kabat E.A., Wu T.T., Perry H.M., Gottesman K.S., Foeller C. Sequences of proteins of immunological interest 1991, U.S. Department of Health and Human Services, Bethesda, MD.
39. Kelley R.F., O'Connell M.P. Thermodynamic analysis of an antibody functional epitope. Biochemistry 1993, 32:6828-6835.
40. Kelley R.F., O'Connell M.P., Carter P., Presta L., Eigenbrot C., Covarrubias M., Snedecor B., Bourell J.H., Vetterlein D. Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185(HER2) antibody Fab fragments. Biochemistry 1992, 31:5434-5441.
41. Khazaeli M.B., Conry R.M., LoBuglio A.F. Human immune response to monoclonal antibodies. J Immunother 1994, 15:42-52.
42. Klimka A., Matthey B., Roovers R.C., Barth S., Arends J.W., Engert A., Hoogenboom H.R. Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning. Br J Cancer 2000, 83:252-260.
43. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
44. Krueger J.G., Walters I.B., Miyazawa M., Gilleaudeau P., Hakimi J., Light S., Sherr A., Gottlieb A.B. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000, 43:448-458.
45. Kuus-Reichel K., Grauer L.S., Karavodin L.M., Knott C., Krusemeier M., Kay N.E. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?. Clin Diagn Lab Immunol 1994, 1:365-372.
46. Landolfi N.F., Thakur A.B., Fu H., Vasquez M., Queen C., Tsurushita N. The integrity of the ball-and-socket joint between V and C domains is essential for complete activity of a humanized antibody. J Immunol 2001, 166:1748-1754.
47. Levy R., Assulin O., Scherf T., Levitt M., Anglister J. Probing antibody diversity by 2D NMR: Comparison of amino acid sequences, predicted structures, and observed antibody-antigen interactions in complexes of two antipeptide antibodies. Biochemistry 1989, 28:7168-7175.
48. Leyland-Jones B., Arnold A., Gelmon K., Verma S., Ayoub J.P., Seidman A., Dias R., Howell J., Rakhit A. Pharmacologic insights into the future of trastuzumab. Ann Oncol 2001, 12:S43-S47.
49. Martin A.C., Thornton J.M. Structural families in loops of homologous proteins: Automatic classification, modelling and application to antibodies. J Mol Biol 1996, 263:800-815.
50. Mateo C., Moreno E., Amour K., Lombardero J., Harris W., Perez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: Recovery of antagonistic activity. Immunotechnology 1997, 3:71-81.
51. Matsuda F., Ishii K., Bourvagnet P., Kuma K., Hayashida H., Miyata T., Honjo T. The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus. J Exp Med 1998, 188:2151-2162.
52. Meindl A., Klobeck H.G., Ohnheiser R., Zachau H.G. The V kappa gene repertoire in the human germ line. Eur J Immunol 1990, 20:1855-1863.
53. Mian I.S., Bradwell A.R., Olson A.J. Structure, function and properties of antibody binding sites. J Mol Biol 1991, 217:133-151.
54. Miller R.A., Maloney D.G., Warnke R., Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. New Engl J Med 1982, 306:517-522.
55. Morea V., Tramontano A., Rustici M., Chothia C., Lesk A.M. Antibody structure, prediction and redesign. Biophys Chem 1997, 68:9-16.
56. Morrison S.L., Johnson M.J., Herzenberg L.A., Oi V.T. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984, 81:6851-6855.
57. Mountain A., Adair J.R. Engineering antibodies for therapy. Biotechnol Genet Eng Rev 1992, 10:1-142.
58. Niemeyer G., Koch M., Light S., Kuse E.R., Nashan B. Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients. Am J Transplant 2002, 2:454-460.
59. Nussenblatt R.B., Fortin E., Schiffman R., Rizzo L., Smith J., Van Veldhuisen P., Stran P., Yaffe A., Goldman C.K., Waldmann T.A., Whitcup S.M. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial. Proc Natl Acad Sci USA 1999, 96:7462-7466.
60. Padlan E.A. On the nature of antibody combining sites: Unusual structural features that may confer on these sites an enhanced capacity for binding ligands. Proteins 1990, 7:112-124.
61. Padlan E.A. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol 1991, 28:489-498.
62. Padlan E.A. Choosing the best framework to use in the humanization of an antibody by CDR-grafting: Suggestion from 3-D structural data 1992, IBC antibody Engineering, San Diego.
63. Padlan E.A. Anatomy of the antibody molecule. Mol Immunol 1994, 31:169-217.
64. Padlan E.A., Abergel C., Tipper J.P. Identification of specificity-determining residues in antibodies. FASEB J 1995, 9:133-139.
65. Pedersen J.T., Henry A.H., Searle S.J., Guild B.C., Roguska M., Rees A.R. Comparison of surface accessible residues in human and murine immunoglobulin Fv domains. Implication for humanization of murine antibodies. J Mol Biol 1994, 235:959-973.
66. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., Winkler M., Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
67. Presta L.G., Lahr S.J., Shields R.L., Porter J.P., Gorman C.M., Fendly B.M., Jardieu P.M. Humanization of an antibody directed against IgE. J Immunol 1993, 151:2623-2632.
68. Przepiorka D., Kernan N.A., Ippoliti C., Papadopoulos E.B., Giralt S., Khouri I., Lu J.G., Gajewski J., Durett A., Cleary K., Champlin R., Andersson B.S., Light S. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graftversus-host disease. Blood 2000, 95:83-89.
69. Queen C., Selick H.E. Chimeric immunoglobulin specific for p55 Tac protein of the IL-2 receptor. WO 90/07861 1990, World Intellectual Property Organization.
70. Queen C., Schneider W.P., Selick H.E., Payne P.W., Landolfi N.F., Duncan J.F., Avdalovic N.M., Levitt M., Junghans R.P., Waldmann T.A. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989, 86:10029-10033.
71. Rader C., Cheresh D.A., Barbas C.F. A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries. Proc Natl Acad Sci USA 1998, 95:8910-8915.
72. Rader C., Ritter G., Nathan S., Elia M., Gout I., Jungbluth A.A., Cohen L.S., Welt S., Old L.J., Barbas C.F. The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. J Biol Chem 2000, 275:13668-13676.
73. Ravetch J.V., Kinet J.P. Fc receptors. Annu Rev Immunol 1991, 9:457-492.
74. Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature 1988, 332:323-327.
75. Roguska M.A., Pedersen J.T., Henry A.H., Searle S.M., Roja C.M., Avery B., Hoffee M., Cook S., Lambert J.M., Blattler W.A., Rees A.R., Guild B.C. A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing. Protein Eng 1996, 9:895-904.
76. Roguska M.A., Pedersen J.T., Keddy C.A., Henry A.H., Searle S.J., Lambert J.M., Goldmacher V.S., Blattler W.A., Rees A.R., Guild B.C. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci USA 1994, 91:969-973.
77. Rosok M.J., Yelton D.E., Harris L.J., Bajorath J., Hellstrom K.E., Hellstrom I., Cruz G.A., Kristensson K., Lin H., Huse W.D., Glaser S.M. A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab. J Biol Chem 1996, 271:22611-22618.
78. Schable K.F., Zachau H.G. The variable genes of the human immunoglobulin kappa locus. Biol Chem Hoppe Seyler 1993, 374:1001-1022.
79. Shalaby M.R., Shepard H.M., Presta L., Rodriques M.L., Beverley P.C.L., Feldmann M., Carter P. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncongene. J Exp Med 1992, 175:217-225.
80. Singer S.S., Kawka D.W., DeMartino J.A., Daugherty B.L., Elliston K.O., Alves K., Bush B.L., Cameron P.M., Cuca G.C., Davies P., et al. Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences. J Immunol 1993, 150:2844-2857.
81. Sorrentino M., Powers T. Effectiveness of palivizumab: Evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr Infect Dis J 2000, 19:1068-1071.
82. Stephens S., Emtage S., Vetterlein O., Chaplin L., Bebbington C., Nesbitt A., Sopwith M., Athwal D., Novak C., Bodmer M. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 1995, 85:668-674.
83. Studnicka G.M., Soares S., Better M., Williams R.E., Nadell R., Horwitz A.H. Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. Protein Eng 1994, 7:805-814.
84. Tamura M., Milenic D.E., Iwahashi M., Padlan E., Schlom J., Kashmiri S.V. Structural correlates of an anticarcinoma antibody: Identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J Immunol 2000, 164:1432-1441.
85. Tan P., Mitchell D.A., Buss T.N., Holmes M.A., Anasetti C., Foote J. "Superhumanized" antibodies: Reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: Application to an anti-CD28. J Immunol 2002, 169:1119-1125.
86. Tempest P.R., Bremner P., Lambert M., Taylor G., Furze J.M., Carr F.J., Harris W.J. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology (NY) 1991, 9:266-271.
87. Thakur A.B., Landolfi N.F. A potent neutralizing monoclonal antibody can discriminate amongst IFNgamma from various primates with greater specificity than can the human IFNgamma receptor complex. Mol Immunol 1999, 36:1107-1115.
88. Tomlinson I.M., Cox J.P.L., Gherardi E., Lesk A.M., Chothia C. The structural repertoire of the human V-kappa domain. EMBO J 1995, 14:4628-4638.
89. Tomlinson I.M., Walter G., Marks J.D., Llewelyn M.B., Winter G. The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol 1992, 227:776-798.
90. Van Assche G., Dalle I., Noman M., Aerden I., Swijsen C., Asnong K., Maes B., Ceuppens J., Geboes K., Rutgeerts P. A pilot study on the use of the humanized anti interleukin-2 antibody, Daclizumab, in active ulcerative colitis. Am J Gastroenterol 2002, In press.
91. Van Assche G., Rutgeerts P. Anti-TNF agents in Crohn's disease. Expert Opin Investig Drugs 2000, 9:103-111.
92. Verhoeyen M., Milstein C., Winter G. Reshaping human antibodies: grafting an antilysozyme activity. Science 1988, 239:1534-1536.
93. Vincenti F., Kirkman R., Light S., Bumgardner G., Pescovitz M., Halloran P., Neylan J., Wilkinson A., Ekberg H., Gaston R., Backman L., Burdick J. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998, 338:161-165.
94. Vincenti F., Lantz M., Birnbaum J., Garovoy M., Mould D., Hakimi J., Nieforth K., Light S. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997, 63:33-38.
95. Wang Z., Wang Y., Li Z., Li J., Dong Z. Humanization of a mouse monoclonal antibody neutralizing TNF-alpha by guided selection. J Immunol Methods 2000, 241:171-184.
96. Ward A.M., Catto J.W., Hamdy F.C. Prostate specific antigen: biology, biochemistry and available commercial assays. Ann Clin Biochem 2001, 38:633-651.
97. Williams S.C., Frippiat J.-P., Tomlinson I.M., Ignatovich O., Lefranc M.-P., Winter G. Sequence and evolution of the human germline V-lambda repertoire. J Mol Biol 1996, 264:220-232.
98. Wu H., Nie Y., Huse W.D., Watkins J.D. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J Mol Biol 1999, 294:151-162.
99. Zachau H.G. The immunoglobulin kappa gene families of human and mouse: a cottage industry approach. Biol Chem 2000, 381:951-954.
100. Zilber B., Scherf T., Levitt M., Anglister J. NMR-derived model for a peptide-antibody complex. Biochemistry 1990, 29:10032-10041.